Summary by Futu AI
On September 30, 2024, Clene Inc., a clinical-stage biopharmaceutical company, announced the entry into a securities purchase agreement with an accredited healthcare-focused institutional investor for a registered direct offering. The agreement includes the sale of 725,000 shares of common stock at $4.713 per share and pre-funded warrants to purchase up to 17,626 shares at the same price, minus $0.001 per warrant. Concurrently, Clene engaged in private placements with existing stockholders and affiliate investors, including directors and executive officers, selling additional shares and warrants. The gross proceeds from these transactions are expected to total approximately $7.3 million, which Clene intends to use for general corporate purposes and the clinical development of its lead drug candidate, CNM-Au8. The offerings are expected to close on October 1, 2024, subject to customary closing conditions. Canaccord Genuity LLC acted as the exclusive placement agent for the offerings. Clene has agreed to register the shares issued in the private placements for resale with the SEC within a specified timeframe.